Kevin Korenblat, MD
Gastroenterology · Saint Louis, MONPI 1326066747
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,550 of the $4,819 with a category attached, or 94.4%. Mallinckrodt Hospital Products Inc. accounts for 94.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $4,564 and has fallen 98.8% since, to $53 in 2024.
Across 11 payments — averaging $438.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$5K
- Gilead$149
- Novo Nordisk$78
- Shionogi Inc$25
- Amgen$18
Across 257 payments — averaging $3315.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$348K
- Boehringer Ingelheim International GmbH$188K
- Bard Peripheral Vascular, Inc.$80K
- AbbVie$78K
- Janssen Research & Development, LLC$56K
- Intercept Pharma Europe Ltd.$55K
- plus $47K from 3 others
What the payments were for
- Consulting fees$4,55094%
- Food & beverage$2696%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 1 | $4,550 |
| Gilead | 7 | $149 |
| Novo Nordisk | 1 | $78 |
| Shionogi Inc | 1 | $25 |
| Amgen | 1 | $18 |
How this compares
$4,819 in reported general payments places this provider in the 70th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 109 | $378,118 |
| Everolimus | 20 | $90,595 |
| Tacrolimus | 455 | $50,817 |
| Envarsus XrTacrolimus | 65 | $46,811 |
| Ursodiol | 292 | $45,380 |
| Entecavir | 93 | $30,350 |
| Mycophenolic AcidMycophenolate Sodium | 137 | $25,304 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $10,913 |
| Tenofovir Disoproxil Fumarate | 30 | $10,407 |
| EliquisApixaban | 17 | $9,406 |
| Sirolimus | 48 | $8,439 |
| Cyclosporine ModifiedCyclosporine, Modified | 30 | $4,938 |
| Lactulose | 77 | $4,489 |
| Mycophenolate Mofetil | 95 | $4,416 |
| Neomycin Sulfate | 48 | $3,952 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Saint Louis
- Gregory SayukSaint Louis$1.1M
- Katie SchroederSaint Louis$730K
- David AlpersSaint Louis$616K
- Parakkal DeepakSaint Louis$205K
- Mauricio Lisker MelmanSaint Louis$179K
- Matthew CiorbaSaint Louis$156K
- Bruce BaconSaint Louis$138K
- Jeffrey CrippinSaint Louis$120K
- Vladimir KushnirSaint Louis$118K
- Kayci Huff-HardySaint Louis$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.